Midcap

Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline

Retrieved on: 
Thursday, November 3, 2022
Biotechnology, Pharmaceutical, Health, Oncology, DNA, RNA transfection, EXEL, Genetics, U.S. Securities and Exchange Commission, Acquisition, Technology, SEC, Solution, Midcap, Compliance, Catalent, Intellectual property, NYSE, A-DNA, Lung, Forward-looking statement, Vaccine, Cancer, Security (finance), Control, Patient, Nobel Prize, Drug discovery, ADC, Research, Breast, COVID-19, S&P, Toxicity, Therapy, Multimedia, Antibody, Industry, Standard, CTLT, Esaxerenone, Nasdaq, Genentech, Daiichi Sankyo, Acceleration, Engineering, AAV, Fine chemical, Pharmaceutical industry, Kerosene, Chemistry, Facebook, Exelixis, Limited

In September 2020, Exelixis and Catalent entered into a separate agreement under which Catalent is applying its SMARTag bioconjugation platform to build ADCs using monoclonal antibodies from Exelixis growing preclinical pipeline.

Key Points: 
  • In September 2020, Exelixis and Catalent entered into a separate agreement under which Catalent is applying its SMARTag bioconjugation platform to build ADCs using monoclonal antibodies from Exelixis growing preclinical pipeline.
  • Exelixis will fund the development work conducted by Catalent until development candidate selection is complete, after which Exelixis will assume responsibility for conducting preclinical, clinical, and commercial activities.
  • We expect the new license agreement with Exelixis will yield innovative and differentiated therapies with the potential to improve care and outcomes for cancer patients.
  • Catalent and SMARTag are registered trademarks of Catalent Pharma Solutions, Inc., or its subsidiaries in the U.S. or other countries.

Exelixis and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805, a Potentially Best-in-Class Monoclonal Antibody Targeting SIRPα

Retrieved on: 
Tuesday, November 1, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Security (finance), SIRP, S&P, Population, Radiation, Acquisition, Toxic epidermal necrolysis, U.S. Securities and Exchange Commission, Pembrolizumab, News, SEC, Daiichi Sankyo, Cancer, Research, Antibody, IND, Nasdaq, COVID-19, Macrophage, Allele, Intellectual property, EXEL, Immune system, Myelocyte, Phagocytosis, Anemia, Thrombocytopenia, Standard, Midcap, ADCP, Compliance, Genentech, Genetics, Therapy, CD47, Antigen presentation, Patient, Multimedia, Esaxerenone, Drug discovery, Forward-looking statement, Tumor microenvironment, Achievement, Vaccine, Pharmaceutical industry, Kerosene, Facebook, Limited, Exelixis

Exelixis, Inc. (Nasdaq: EXEL) and Sairopa B.V. (Sairopa) today announced that the companies have entered into an exclusive clinical development and option agreement for ADU-1805, a potentially best-in-class monoclonal antibody that targets SIRP.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) and Sairopa B.V. (Sairopa) today announced that the companies have entered into an exclusive clinical development and option agreement for ADU-1805, a potentially best-in-class monoclonal antibody that targets SIRP.
  • With an Investigational New Drug filing anticipated in the first quarter of 2023, this agreement provides an exciting opportunity to expand our clinical pipeline.
  • Sairopa was founded to develop a portfolio of therapeutic antibodies that modulate immune system activity to provide benefit to cancer patients.
  • Exelixis, the Exelixis logo, CABOMETYX and COMETRIQ are registered U.S. trademarks of Exelixis.

Exelixis and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12, a Potential First-in-Class Peptide-Drug Conjugate of Exatecan

Retrieved on: 
Tuesday, November 1, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Therapeutic index, Peptide, PDC, SEC, Research, COVID-19, EXEL, Metabolism, Compliance, Esaxerenone, Drug development, S&P, Pharmacotherapy, CEO, Nasdaq, Cell, Safety, Technology, University, U.S. Securities and Exchange Commission, Patient, Ovarian cancer, Multimedia, Neoplasm, Lactic acid, Therapy, Yale University, Security (finance), Control, Acquisition, EORTC, Daiichi Sankyo, Cancer, Standard, Biology, Tumor microenvironment, Toxicity, Intellectual property, ENA, Midcap, Genentech, Genetics, Breast, Forward-looking statement, Drug discovery, Pharmaceutical industry, Vaccine, Kerosene, Limited, Exelixis, Facebook

Exelixis, Inc. (Nasdaq: EXEL) and Cybrexa Therapeutics (Cybrexa) today announced that the companies have entered into an exclusive collaboration agreement providing Exelixis the right to acquire CBX-12 (alphalex exatecan), a clinical-stage, first-in-class peptide-drug conjugate (PDC) that utilizes Cybrexas proprietary alphalex technology to enhance delivery of exatecan to tumor cells.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) and Cybrexa Therapeutics (Cybrexa) today announced that the companies have entered into an exclusive collaboration agreement providing Exelixis the right to acquire CBX-12 (alphalex exatecan), a clinical-stage, first-in-class peptide-drug conjugate (PDC) that utilizes Cybrexas proprietary alphalex technology to enhance delivery of exatecan to tumor cells.
  • This collaboration underscores Exelixis commitment to expanding its clinical pipeline building upon its biotherapeutics and targeted drug therapy expertise.
  • "This agreement aligns with Exelixis goal of acquiring first- or best-in-class clinical-stage assets that may provide differentiated benefits to patients with cancer.
  • Exelixis, the Exelixis logo, CABOMETYX and COMETRIQ are registered U.S. trademarks of Exelixis.

Exelixis Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 1, 2022
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Marketing, PFS, Population, European Society for Medical Oncology, Relatlimab, SEC, Research, COVID-19, Progression-free survival, EXEL, Compliance, Pharmacokinetics, Webcast, Esaxerenone, Royalty payment, Ipilimumab, Initial, News, Software, S&P, Oncology, Partnership, OS, Nasdaq, Safety, RNAi nanoparticles to target cancer, Technology, Investor, U.S. Securities and Exchange Commission, T helper cell, ESMO, Security (finance), Bristol Myers Squibb, Control, Ipsen, Acquisition, Daiichi Sankyo, Cancer, Standard, ADC, LAG-3, BMS, Stimulator, Congress, Atezolizumab, RCC, ENA, Midcap, Genentech, Genetics, Clinical trial, Stimulator of interferon genes, Forward-looking statement, Drug discovery, Calendar, Pharmaceutical industry, Communications satellite, Kerosene, Air cargo, Nivolumab, Limited, Takeda, Patient, Exelixis, Facebook

In the third quarter of 2022, global cabozantinib franchise net product revenues generated by Exelixis and its partners were almost $500 million.

Key Points: 
  • In the third quarter of 2022, global cabozantinib franchise net product revenues generated by Exelixis and its partners were almost $500 million.
  • Exelixis earned $30.3 million in royalty revenues during the quarter ended September 30, 2022, pursuant to collaboration agreements with its partners, Ipsen and Takeda.
  • Previously, in July, Exelixis announced that COSMIC-313 met its primary endpoint, demonstrating significant improvement in PFS at the primary analysis.
  • Exelixis management will discuss the companys financial results for the third quarter of 2022 and provide a general business update during a conference call beginning at 5:00 p.m.

Atlantica to Present Third Quarter 2022 Financial Results on November 9

Retrieved on: 
Friday, October 28, 2022
NASDAQ, Atlantica, Conference, Edison Electric Institute, Webcast, BNP Paribas, Midcap, Natural gas, CFO, Renewable energy, Online shopping, EMEA

October 28, 2022 Atlantica Sustainable Infrastructure (NASDAQ: AY) announced today that it will release its financial results for the third quarter of 2022 before the opening of the market on Wednesday, November 9, 2022.

Key Points: 
  • October 28, 2022 Atlantica Sustainable Infrastructure (NASDAQ: AY) announced today that it will release its financial results for the third quarter of 2022 before the opening of the market on Wednesday, November 9, 2022.
  • Atlanticas CEO, Santiago Seage and CFO, Francisco Martinez-Davis, will hold a conference call and a webcast on Wednesday, November 9, 2022, at 8:15 am (New York time).
  • Please visit the website 15 minutes earlier in order to register for the live webcast and download any necessary audio software.
  • Atlantica advises participants to access the conference call at least 20 minutes in advance.

F.N.B. Corporation's Banking Subsidiary Receives Award for Commitment to Diversity, Equity and Inclusion

Retrieved on: 
Thursday, October 20, 2022
F.N.B. Corporation, Insurance, Top, High Point, New, Culture, Piedmont Triad, Government, Standard, Millennial Women, Forbes, Organization, GICS, NYSE, Diversity, Award, District, Global, Georgia Railroad and Banking Company, S&P Global Ratings, Midcap, Multimedia, Woman, DEI, FNB, Company, World, Leadership, Workplace, Small business, Winston-Salem, North Carolina, Innovation, Equity, Recognition, Financial services, First National Bank, Solution, Property management, Management

PITTSBURGH, Oct. 20, 2022 /PRNewswire/ -- F.N.B. Corporation (NYSE: FNB) announced that its banking subsidiary, First National Bank, has been recognized with the Top Workplaces 2022 Culture Excellence award for Diversity, Equity and Inclusion (DEI) Practices. The national award celebrates organizations that are committed to creating a welcoming and inclusive place to work for all employees.

Key Points: 
  • Corporation (NYSE: FNB) announced that its banking subsidiary, First National Bank, has been recognized with the Top Workplaces 2022 Culture Excellence award for Diversity, Equity and Inclusion (DEI) Practices.
  • The national award celebrates organizations that are committed to creating a welcoming and inclusive place to work for all employees.
  • Commercial banking solutions includecorporate banking, small business banking, investment real estate financing, government banking, business credit, capital markets and lease financing.
  • The consumer banking segment provides a full line of consumer banking products and services, including deposit products, mortgage lending, consumer lending and a complete suite of mobile and online banking services.

CAPTRUST ADDS MASSACHUSETTS-BASED PATRIOT PENSION ADVISORS

Retrieved on: 
Wednesday, October 19, 2022
PPA, Advisor Group, Patriot, Midcap, Retirement, Multimedia, Marketing, Industry, View, Foundation, Compliance, Financial adviser

RALEIGH, N.C., Oct. 19, 2022 /PRNewswire/ -- CAPTRUST Financial Advisors (CAPTRUST) today announced the addition of Patriot Pension Advisors (PPA) based in Foxborough, Massachusetts.

Key Points: 
  • RALEIGH, N.C., Oct. 19, 2022 /PRNewswire/ -- CAPTRUST Financial Advisors (CAPTRUST) today announced the addition of Patriot Pension Advisors (PPA) based in Foxborough, Massachusetts.
  • The firm oversees more than $900 million in client assets andis led by Ted Burke, who will be joining CAPTRUST, along with his colleague Michelle Marchionni.
  • "And that's why we decided to grow with CAPTRUST.
  • Consistent with other transactions, Patriot will take on the CAPTRUST brand.MidCap Advisors served as PPA's financial advisor in the transaction.

Exelixis to Release Third Quarter 2022 Financial Results on Tuesday, November 1, 2022

Retrieved on: 
Tuesday, October 18, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Webcast, Investor, Standard, Patient, Midcap, Twitter, S&P, Nasdaq, Software, Esaxerenone, Drug discovery, Calendar, Internet, Genentech, Daiichi Sankyo, EXEL, Genetics, News, Cancer, Pharmaceutical industry, Kerosene, Facebook, Exelixis, Limited

Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2022 financial results will be released on Tuesday, November 1, 2022 after the markets close.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2022 financial results will be released on Tuesday, November 1, 2022 after the markets close.
  • ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update.
  • For more information about Exelixis, please visit www.exelixis.com , follow @ ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
  • Exelixis, the Exelixis logo, CABOMETYX and COMETRIQ are registered U.S. trademarks of Exelixis.

Surmodics Announces New Credit Facilities Providing up to $125 Million in Financing

Retrieved on: 
Monday, October 17, 2022
Biotechnology, General Health, Health, Medical Devices, Benchmark, U.S. Securities and Exchange Commission, CBA, Disease, SEC, Growth, Borrowing base, Investor, Postmarketing surveillance, Food and Drug Administration, Annual report, DCB, Midcap, Security (finance), Nasdaq, Wells Fargo, Private Securities Litigation Reform Act, Food, Company, Acquisition, CEO, Exchange, Forward-looking statement, Failure, FDA, Compliance, Abbott, Pharmaceutical industry, Bank

The Company drew $25 million on the term loan and $5 million on the revolving credit facility at close.

Key Points: 
  • The Company drew $25 million on the term loan and $5 million on the revolving credit facility at close.
  • These proceeds were partially used to retire the Companys existing $25 million revolving credit facility with Bridgewater Bank, of which $10 million was outstanding.
  • Additional draws on the term loan may be made in $10 million minimum increments, up to a total of $75 million through December 31, 2024.
  • Availability to draw on the five-year, $25 million revolving credit facility is based primarily on the Companys inventory and receivable balances.

Bird Amends its Apollo Vehicle Financing Credit Facility

Retrieved on: 
Tuesday, October 11, 2022
Finance, Alternative Vehicles, Fuels, Professional Services, Automotive, EV, Electric Vehicles, Bird, NYSE, Company, Global, Apollo, Midcap, City, Transport, Form

Bird Global, Inc. (Bird or the Company) (NYSE:BRDS), a leader in eco-friendly electric transportation, today announced that its subsidiary, Bird Rides, Inc., has amended its existing $150 million vehicle financing credit facility with MidCap Financial Investment Corporation and MidCap Financial Trust (each managed or advised by Apollo Capital Management, L.P. or its affiliates, collectively "Apollo").

Key Points: 
  • Bird Global, Inc. (Bird or the Company) (NYSE:BRDS), a leader in eco-friendly electric transportation, today announced that its subsidiary, Bird Rides, Inc., has amended its existing $150 million vehicle financing credit facility with MidCap Financial Investment Corporation and MidCap Financial Trust (each managed or advised by Apollo Capital Management, L.P. or its affiliates, collectively "Apollo").
  • Apollo has been a supportive, long-standing partner, helping us structure a first-of-its kind micro mobility vehicle financing facility to cover substantially all of our global vehicle capital expenditures.
  • The amendment provides the Company meaningful financial and operational flexibility, along with cash management benefits, said Ben Lu, chief financial officer of Bird Global, Inc.
    "We are pleased to continue to support Bird through an amendment of the credit facility.
  • Bird is an electric vehicle company dedicated to bringing affordable, environmentally-friendly transportation solutions such as e-scooters and e-bikes to communities across the world.